GUILIN SANJIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.58 CNY | +0.40% |
|
-0.40% | -13.18% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,555 | 7,643 | 8,577 | 9,728 | 7,570 | 8,514 |
| Enterprise Value (EV) 1 | 6,342 | 6,588 | 7,291 | 8,638 | 6,609 | 7,636 |
| P/E ratio | 18.3 x | 19.6 x | 31.1 x | 28.2 x | 23.6 x | 20.1 x |
| Yield | 2.73% | 1.75% | 2.68% | 5.32% | 6.05% | 4.14% |
| Capitalization / Revenue | 4.77 x | 4.66 x | 5.48 x | 5.59 x | 3.86 x | 3.92 x |
| EV / Revenue | 4 x | 4.02 x | 4.65 x | 4.96 x | 3.37 x | 3.52 x |
| EV / EBITDA | 11.5 x | 12.5 x | 18.6 x | 21.4 x | 16.2 x | 13.7 x |
| EV / FCF | 18.6 x | 51.3 x | 24.3 x | 57.2 x | 26.5 x | 21.8 x |
| FCF Yield | 5.39% | 1.95% | 4.11% | 1.75% | 3.77% | 4.6% |
| Price to Book | 2.69 x | 2.68 x | 2.9 x | 3.43 x | 2.76 x | 3.02 x |
| Nbr of stocks (in thousands) | 590,200 | 582,516 | 575,273 | 575,273 | 572,641 | 587,569 |
| Reference price 2 | 12.80 | 13.12 | 14.91 | 16.91 | 13.22 | 14.49 |
| Announcement Date | 4/23/19 | 4/27/20 | 4/28/21 | 4/26/22 | 4/27/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,585 | 1,640 | 1,566 | 1,741 | 1,960 | 2,172 |
| EBITDA 1 | 551.9 | 527.8 | 392.3 | 402.8 | 408.8 | 556.4 |
| EBIT 1 | 477 | 438 | 313.3 | 318.4 | 315.7 | 462.9 |
| Operating Margin | 30.1% | 26.7% | 20% | 18.28% | 16.11% | 21.31% |
| Earnings before Tax (EBT) 1 | 495.7 | 467.6 | 344.2 | 429.1 | 446.2 | 518.3 |
| Net income 1 | 413.3 | 392.1 | 277 | 343.7 | 329.5 | 421.3 |
| Net margin | 26.08% | 23.9% | 17.68% | 19.74% | 16.81% | 19.4% |
| EPS 2 | 0.7000 | 0.6700 | 0.4800 | 0.6000 | 0.5600 | 0.7200 |
| Free Cash Flow 1 | 341.6 | 128.4 | 299.8 | 151.1 | 249.4 | 350.9 |
| FCF margin | 21.55% | 7.83% | 19.14% | 8.68% | 12.73% | 16.16% |
| FCF Conversion (EBITDA) | 61.89% | 24.33% | 76.42% | 37.52% | 61.01% | 63.07% |
| FCF Conversion (Net income) | 82.64% | 32.75% | 108.23% | 43.97% | 75.68% | 83.29% |
| Dividend per Share 2 | 0.3500 | 0.2300 | 0.4000 | 0.9000 | 0.8000 | 0.6000 |
| Announcement Date | 4/23/19 | 4/27/20 | 4/28/21 | 4/26/22 | 4/27/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,213 | 1,055 | 1,286 | 1,090 | 961 | 878 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 342 | 128 | 300 | 151 | 249 | 351 |
| ROE (net income / shareholders' equity) | 15.1% | 14% | 9.59% | 11.9% | 11.7% | 15% |
| ROA (Net income/ Total Assets) | 8.99% | 8.03% | 5.37% | 4.99% | 4.89% | 7.32% |
| Assets 1 | 4,600 | 4,886 | 5,162 | 6,891 | 6,732 | 5,753 |
| Book Value Per Share 2 | 4.760 | 4.890 | 5.140 | 4.940 | 4.790 | 4.790 |
| Cash Flow per Share 2 | 2.060 | 2.030 | 2.370 | 2.570 | 2.150 | 1.800 |
| Capex 1 | 90 | 226 | 205 | 144 | 62.3 | 76.4 |
| Capex / Sales | 5.68% | 13.79% | 13.12% | 8.28% | 3.18% | 3.52% |
| Announcement Date | 4/23/19 | 4/27/20 | 4/28/21 | 4/26/22 | 4/27/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.18% | 1.02B | |
| +12.92% | 4.95B | |
| -32.29% | 3.6B | |
| -4.28% | 3.03B | |
| -24.21% | 2.66B | |
| -8.82% | 2.34B | |
| +39.33% | 1.85B | |
| +40.81% | 1.45B | |
| -14.27% | 1.41B | |
| +41.90% | 1.38B |
- Stock Market
- Equities
- 002275 Stock
- Financials Guilin Sanjin Pharmaceutical Co., Ltd.
